SRDX - Surmodics Inc Stock Price, Fair Value and News

26.20USD+0.13 (+0.50%)Market Closed

Market Summary

USD26.20+0.13

Market Closed

0.50%

SRDX Stock Price

View Fullscreen

SRDX RSI Chart

SRDX Valuation

Market Cap

373.0M

Price/Earnings (Trailing)

67.56

Price/Sales (Trailing)

2.7

EV/EBITDA

17.18

Price/Free Cashflow

37.82

SRDX Price/Sales (Trailing)

SRDX Profitability

EBT Margin

7.07%

Return on Equity

4.52%

Return on Assets

3.06%

Free Cashflow Yield

2.64%

SRDX Fundamentals

SRDX Revenue

Revenue (TTM)

138.2M

Rev. Growth (Yr)

22.54%

Rev. Growth (Qtr)

9.23%

SRDX Earnings

Earnings (TTM)

5.5M

Earnings Growth (Yr)

89.98%

Earnings Growth (Qtr)

-111.74%

Breaking Down SRDX Revenue

Last 7 days

-0.7%

Last 30 days

-7.1%

Last 90 days

-23.7%

Trailing 12 Months

8.1%

How does SRDX drawdown profile look like?

SRDX Financial Health

Current Ratio

4.84

Debt/Equity

0.24

Debt/Cashflow

0.43

SRDX Investor Care

Shares Dilution (1Y)

0.79%

Diluted EPS (TTM)

0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	103.0M	130.6M	132.6M	138.2M
2022	97.0M	97.9M	100.0M	101.9M
2021	106.7M	103.7M	105.1M	105.8M
2020	100.6M	103.1M	94.9M	94.5M
2019	90.2M	92.3M	100.1M	100.5M
2018	73.9M	78.4M	81.3M	86.6M
2017	73.4M	71.2M	73.1M	72.4M
2016	66.5M	70.6M	71.4M	72.6M
2015	58.6M	59.9M	61.9M	64.2M
2014	56.1M	56.4M	57.4M	57.8M
2013	56.1M	56.1M	56.1M	56.2M
2012	54.4M	55.7M	56.1M	56.1M
2011	53.6M	53.2M	52.8M	54.1M
2010	0	88.0M	54.5M	54.1M
2009	0	0	121.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Surmodics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 08, 2024	kalich ronald b sr	acquired	-	-	1,803	-
Feb 08, 2024	dantzker david	acquired	-	-	1,803	-
Feb 08, 2024	bedoya jose h	acquired	94,171	23.95	3,932	-
Feb 08, 2024	knight susan e	acquired	-	-	1,944	-
Feb 08, 2024	heine lisa wipperman	acquired	-	-	1,803	-
Feb 08, 2024	bedoya jose h	acquired	-	-	1,803	-
Feb 08, 2024	bedoya jose h	sold (taxes)	-94,203	31.89	-2,954	-
Feb 05, 2024	knight susan e	sold (taxes)	-94,187	30.75	-3,063	-
Feb 05, 2024	knight susan e	acquired	94,171	23.95	3,932	-
Jan 19, 2024	dantzker david	sold (taxes)	-94,198	33.97	-2,773	-

Which funds bought or sold SRDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Assenagon Asset Management S.A.	reduced	-0.04	-170,839	713,666	-%
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	added	0.01	-487,552	2,041,540	0.12%
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.15	-57,000	14,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	31,972	272,807	-%
Apr 19, 2024	Mesirow Financial Investment Management, Inc.	new	-	223,395	223,395	1.11%
Apr 19, 2024	Financial Perspectives, Inc	unchanged	-	-42,158	176,451	0.07%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	-63.00	264	-%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	reduced	-6.88	-1,173,180	3,550,140	0.12%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	0.82	-236,312	1,032,880	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	587	587	-%

Are Funds Buying or Selling SRDX?

Are funds buying SRDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRDX

No. of Funds

Unveiling Surmodics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	6.04%	859,287	SC 13G/A
Feb 09, 2024	morgan stanley	8.1%	1,152,945	SC 13G
Feb 09, 2024	trigran investments, inc.	16.6%	2,358,300	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	5.4%	771,700	SC 13G/A
Jan 29, 2024	millennium management llc	4.7%	671,551	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	1,080,288	SC 13G/A
Apr 06, 2023	blackrock inc.	7.2%	1,014,756	SC 13G/A
Mar 20, 2023	millennium management llc	5.6%	792,190	SC 13G
Feb 14, 2023	soleus capital master fund, l.p.	5.5%	775,311	SC 13G/A
Feb 13, 2023	renaissance technologies llc	4.11%	581,238	SC 13G/A

Recent SEC filings of Surmodics Inc

View All Filings

Date Filed	Form Type	Document
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 12, 2024	8-K	Current Report
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	4	Insider Trading
Feb 12, 2024	4	Insider Trading
Feb 09, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G	Major Ownership Report
Feb 07, 2024	4	Insider Trading

Peers (Alternatives to Surmodics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-4.14%	-1.72%	32.41	4.62	-8.12%	-17.45%
BDX	66.6B	19.5B	-4.72%	-10.85%	53.01	3.42	4.02%	-22.04%
ALGN	23.3B	3.9B	-2.96%	-12.43%	52.39	6.04	3.42%	23.09%
BAX	20.4B	14.8B	-3.18%	-12.72%	7.69	1.38	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.07%	-10.32%	22.5	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.98%	21.26%	32.57	2.66	4.97%	18.89%
BIO	8.0B	2.7B	-19.10%	-36.82%	-12.63	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-6.58%	-25.82%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-3.44%	15.93%	-559.62	9.27	33.86%	89.83%
PDCO	2.3B	6.6B	-4.62%	-2.20%	11.94	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-14.98%	-16.46%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.3M	166.7M	0.99%	-2.77%	-4.6	2.28	6.67%	-456.34%
ANGO	231.9M	324.0M	7.22%	-30.16%	-1.21	0.72	-3.19%	-337.41%
APYX	50.2M	52.3M	13.28%	-50.68%	-2.68	0.96	17.61%	19.28%
AEMD	3.9M	3.7M	-14.29%	284.62%	-0.32	1.05	5.77%	8.23%

Surmodics Inc News

Latest updates

Surmodics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.2%	30,552	27,970	52,483	27,198	24,933	25,988	24,854	26,106	23,003	23,971	23,873	34,995	22,297	22,543	26,883	22,822	22,616	30,816	24,344	22,676	22,241
Costs and Expenses	1.5%	30,874	30,420	31,071	33,781	32,162	32,601	31,997	31,006	26,444	24,460	26,257	25,512	22,204	24,536	25,719	22,978	22,882	26,941	23,327	21,811	21,529
S&GA Expenses	-2.1%	12,537	12,807	12,874	12,967	13,236	13,776	12,854	11,113	9,192	7,862	7,885	7,907	7,023	7,300	7,416	6,733	6,943	7,186	5,939	4,876	5,949
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,321	13,555	11,486
EBITDA Margin	46.0%	0.16*	0.11*	0.08*	-0.18*	-0.16*	-0.13*	-0.07*	-0.02*	0.11*	0.14*	0.12*	0.15*	-	-	-	-	-	-	-	-	-
Interest Expenses	0.1%	896	895	884	884	826	188	145	129	136	132	59.00	59.00	60.00	34.00	29.00	30.00	40.00	40.00	38.00	37.00	37.00
Income Taxes	101.1%	100	-9,461	13,300	368	-200	7,933	-1,530	-919	-700	-279	776	1,400	200	869	-1,200	-1,947	-300	585	-300	-162	-176
Earnings Before Taxes	74.0%	-724	-2,789	20,649	-7,365	-8,008	-6,792	-7,181	-5,002	-3,518	-562	-2,511	9,525	-106	-2,078	1,211	-485	-102	4,118	1,206	1,100	1,134
EBT Margin	276.9%	0.07*	0.02*	-0.01*	-0.28*	-0.26*	-0.23*	-0.17*	-0.12*	0.03*	0.06*	0.05*	0.08*	-	-	-	-	-	-	-	-	-
Net Income	-111.7%	-786	6,694	7,346	-7,733	-7,843	-14,728	-5,651	-4,083	-2,812	8,087	-3,287	8,087	-274	-2,946	2,459	1,462	148	3,554	1,466	1,262	1,310
Net Income Margin	444.8%	0.04*	-0.01*	-0.18*	-0.35*	-0.32*	-0.27*	-0.05*	-0.02*	0.10*	0.12*	0.02*	0.07*	-	-	-	-	-	-	-	-	-
Free Cashflow	-1994.8%	-9,512	502	25,421	-6,548	-11,779	-3,072	-4,358	-5,355	-7,808	-1,516	1,854	15,361	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.0%	180	186	189	166	170	158	176	184	185	195	177	177	164	169	166	156	155	160	150	151	151
Current Assets	-7.9%	80.00	87.00	86.00	61.00	64.00	58.00	60.00	65.00	65.00	70.00	94.00	93.00	81.00	87.00	88.00	77.00	73.00	81.00	70.00	72.00	71.00
Cash Equivalents	-43.6%	23.00	41.00	45.00	19.00	26.00	19.00	20.00	25.00	27.00	31.00	62.00	48.00	36.00	31.00	36.00	15.00	9.00	30.00	29.00	22.00	14.00
Inventory	-2.7%	14.00	15.00	15.00	14.00	13.00	12.00	11.00	9.00	8.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	5.00	5.00	4.00	4.00	4.00
Net PPE	-1.8%	26.00	26.00	27.00	28.00	28.00	27.00	28.00	29.00	29.00	30.00	29.00	30.00	30.00	30.00	29.00	30.00	31.00	30.00	30.00	30.00	30.00
Goodwill	3.1%	44.00	43.00	44.00	44.00	43.00	41.00	43.00	44.00	45.00	46.00	19.00	27.00	28.00	27.00	27.00	26.00	27.00	26.00	27.00	27.00	27.00
Liabilities	-11.7%	58.00	66.00	76.00	64.00	62.00	50.00	51.00	51.00	48.00	55.00	36.00	35.00	30.00	38.00	36.00	31.00	32.00	37.00	32.00	36.00	37.00
Current Liabilities	-31.2%	16.00	24.00	32.00	19.00	17.00	32.00	29.00	28.00	26.00	30.00	18.00	16.00	12.00	19.00	16.00	13.00	14.00	20.00	17.00	20.00	20.00
Short Term Borrowings	-	-	-	-	-	-	10.00	10.00	10.00	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	0.1%	29.00	29.00	29.00	29.00	29.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	29.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	1.9%	122	120	112	103	107	108	125	133	137	140	141	142	133	131	131	125	123	123	119	115	114
Retained Earnings	-0.9%	86.00	87.00	81.00	73.00	81.00	89.00	104	109	113	116	116	120	112	112	115	112	111	111	107	106	104
Additional Paid-In Capital	2.5%	38.00	37.00	34.00	32.00	30.00	29.00	27.00	25.00	23.00	22.00	20.00	19.00	16.00	15.00	14.00	11.00	10.00	11.00	9.00	8.00	6.00
Shares Outstanding	0.6%	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	14.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	310	-	-	-	613	-	-	-	752	-	-	-	219	-	-	-	389	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-803.4%	-8,792	1,250	25,891	-5,825	-10,802	-2,500	-3,497	-4,200	-7,026	889	2,755	16,015	-4,270	1,314	11,439	2,166	-909	12,520	-544	1,467	-5,405
Share Based Compensation	1.3%	1,968	1,943	1,915	1,782	1,965	1,859	1,799	1,719	1,680	1,545	1,456	1,429	1,433	1,416	1,340	1,304	1,393	1,568	1,319	959	1,231
Cashflow From Investing	-82.1%	-8,470	-4,652	-470	-723	-977	1,428	-861	2,445	3,218	-41,882	11,174	-4,404	9,874	-7,195	8,878	5,255	-16,004	-11,469	6,951	6,429	7,843
Cashflow From Financing	-350.4%	-1,049	419	-19.00	-794	18,800	298	-13.00	-37.00	-623	10,029	55.00	933	-790	160	839	-1,182	-4,465	446	3.00	211	-11,689

SRDX Income Statement

2023-12-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 30,552	$ 24,933
Operating costs and expenses:
Cost, Product and Service [Extensible Enumeration]	Product Sales [Member]	Product Sales [Member]
Product costs	$ 8,803	$ 5,267
Research and development	8,664	12,743
Selling, general and administrative	12,537	13,236
Acquired intangible asset amortization	870	913
Contingent consideration expense		3
Total operating costs and expenses	30,874	32,162
Operating loss	(322)	(7,229)
Other expense:
Interest expense, net	(896)	(826)
Foreign exchange loss	(45)	(125)
Investment income, net	539	172
Other expense, net	(402)	(779)
Loss before income taxes	(724)	(8,008)
Income tax (expense) benefit	(62)	165
Net loss	$ (786)	$ (7,843)
Basic net loss per share	$ (0.06)	$ (0.56)
Diluted net loss per share	$ (0.06)	$ (0.56)
Weighted average number of shares outstanding:
Basic	14,102	13,983
Diluted	14,102	13,983
Product Sales [Member]
Revenue:
Total revenue	$ 18,827	$ 14,234
Royalties and License Fees [Member]
Revenue:
Total revenue	9,179	8,765
Research, Development and Other [Member]
Revenue:
Total revenue	$ 2,546	$ 1,934

SRDX Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023
Current Assets:
Cash and cash equivalents	$ 23,355	$ 41,419
Available-for-sale securities	11,819	3,933
Accounts receivable, net of allowances of $86 and $80 as of December 31, 2023 and September 30, 2023, respectively	12,919	10,850
Contract assets	9,178	7,796
Inventories, net	14,438	14,839
Income tax receivable	361	491
Prepaids and other	7,738	7,363
Total Current Assets	79,808	86,691
Property and equipment, net	25,563	26,026
Intangible assets, net	26,213	26,206
Goodwill	44,283	42,946
Other assets	4,373	3,864
Total Assets	180,240	185,733
Current Liabilities:
Accounts payable	2,581	2,993
Accrued liabilities:
Compensation	4,079	10,139
Accrued other	5,809	6,444
Deferred revenue	4,008	4,378
Total Current Liabilities	16,477	23,954
Long-term debt, net	29,443	29,405
Deferred revenue, less current portion	1,648	2,400
Deferred income taxes	1,992	2,004
Other long-term liabilities	8,530	8,060
Total Liabilities	58,090	65,823
Commitments and Contingencies (Note 11)
Stockholders’ Equity:
Series A Preferred stock - $.05 par value, 450 shares authorized; no shares issued and outstanding
Common stock - $.05 par value, 45,000 shares authorized; 14,235 and 14,155 shares issued and outstanding as of December 31, 2023 and September 30, 2023, respectively	712	708
Additional paid-in capital	37,621	36,706
Accumulated other comprehensive loss	(2,652)	(4,759)
Retained earnings	86,469	87,255
Total Stockholders’ Equity	122,150	119,910
Total Liabilities and Stockholders’ Equity	$ 180,240	$ 185,733

About Surmodics Inc

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

CEO	Mr. Gary R. Maharaj
WEBSITE	surmodics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	447

Surmodics Inc Frequently Asked Questions

What is the ticker symbol for Surmodics Inc? What does SRDX stand for in stocks?

SRDX is the stock ticker symbol of Surmodics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Surmodics Inc (SRDX)?

As of Thu Apr 25 2024, market cap of Surmodics Inc is 372.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRDX stock?

You can check SRDX's fair value in chart for subscribers.

What is the fair value of SRDX stock?

You can check SRDX's fair value in chart for subscribers. The fair value of Surmodics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Surmodics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Surmodics Inc a good stock to buy?

The fair value guage provides a quick view whether SRDX is over valued or under valued. Whether Surmodics Inc is cheap or expensive depends on the assumptions which impact Surmodics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRDX.

What is Surmodics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, SRDX's PE ratio (Price to Earnings) is 67.56 and Price to Sales (PS) ratio is 2.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Surmodics Inc's stock?

In the past 10 years, Surmodics Inc has provided 0.017 (multiply by 100 for percentage) rate of return.